TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ocumension Therapeutics ( (HK:1477) ) has issued an update.
Ocumension Therapeutics has reported a significant increase in revenue for the year ended December 31, 2024, attributed to the acquisition and in-licensing of new products, as well as increased sales of ophthalmic pharmaceutical products. The company’s enhanced product portfolio, particularly in dry eye treatments, has strengthened its competitive position in the ophthalmic drug market, leading to a stable revenue source and steady growth of its core products.
More about Ocumension Therapeutics
Ocumension Therapeutics is a pharmaceutical company incorporated in the Cayman Islands, focusing on ophthalmic drugs. The company is committed to providing comprehensive and advanced treatment solutions, particularly in the field of dry eye, and aims to expand its market share through its strong commercialization and localization capabilities.
YTD Price Performance: -9.33%
Average Trading Volume: 1,504,122
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$3.44B
Find detailed analytics on 1477 stock on TipRanks’ Stock Analysis page.